Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal midazolam for terminal agitation in palliative care
2021-004789-36Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of midazolam in terminal agitation (2 arms), sponsored by Heidelberg University. Primary endpoint: Improvement in RASS-PAL after intranasal midazolam. Started Mar 2022; status: completed.
02
Drugs
midazolam
03
Conditions
terminal agitation
Beyond the preview
Go deeper on 2021-004789-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004789-36.